HN2003000090A - Compuestos que modulan la actividad de ppar - Google Patents

Compuestos que modulan la actividad de ppar

Info

Publication number
HN2003000090A
HN2003000090A HN2003000090A HN2003000090A HN2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A HN 2003000090 A HN2003000090 A HN 2003000090A
Authority
HN
Honduras
Prior art keywords
ppar
modulate
activity
compounds
formulations
Prior art date
Application number
HN2003000090A
Other languages
English (en)
Spanish (es)
Inventor
Xue-Min Cheng
Noe Quano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HN2003000090A publication Critical patent/HN2003000090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HN2003000090A 2002-03-07 2003-03-06 Compuestos que modulan la actividad de ppar HN2003000090A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
HN2003000090A true HN2003000090A (es) 2004-05-05

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000090A HN2003000090A (es) 2002-03-07 2003-03-06 Compuestos que modulan la actividad de ppar

Country Status (29)

Country Link
US (1) US20030207924A1 (https=)
EP (1) EP1482935B1 (https=)
JP (1) JP2005528348A (https=)
KR (1) KR20040091693A (https=)
AP (1) AP2004003124A0 (https=)
AR (1) AR038881A1 (https=)
AT (1) ATE405260T1 (https=)
AU (1) AU2003206059A1 (https=)
BR (1) BR0308277A (https=)
CA (1) CA2478520A1 (https=)
CO (1) CO5601012A2 (https=)
DE (1) DE60323060D1 (https=)
EA (1) EA200400943A1 (https=)
EC (1) ECSP045285A (https=)
ES (1) ES2310650T3 (https=)
HN (1) HN2003000090A (https=)
IS (1) IS7377A (https=)
MA (1) MA27181A1 (https=)
MX (1) MXPA04007564A (https=)
NO (1) NO20044242L (https=)
OA (1) OA12780A (https=)
PA (1) PA8567801A1 (https=)
PE (1) PE20030989A1 (https=)
PL (1) PL372969A1 (https=)
TN (1) TNSN04168A1 (https=)
TW (1) TW200305403A (https=)
UY (1) UY27695A1 (https=)
WO (1) WO2003074050A1 (https=)
ZA (1) ZA200406068B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
CN1791592B (zh) * 2003-05-19 2012-07-04 Irm责任有限公司 免疫抑制剂化合物和组合物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
JP5299810B2 (ja) * 2004-02-27 2013-09-25 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
CN101146784B (zh) * 2005-02-25 2012-09-05 财团法人首尔大学校产学协力财团 作为PPARδ配体的噻唑衍生物及其制造方法
JP4869338B2 (ja) * 2005-05-07 2012-02-08 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖因子活性化受容体δリガンドの製造方法及びこれを製造するための中間体
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
JP5084503B2 (ja) * 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
AU2007292816B2 (en) 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
CN102083783A (zh) 2007-10-10 2011-06-01 安姆根有限公司 取代的联苯gpr40调节剂
US20090163481A1 (en) * 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
JP2011507909A (ja) 2007-12-20 2011-03-10 エンビボ ファーマシューティカルズ インコーポレイテッド 四置換ベンゼン
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6204277B1 (en) * 1996-08-19 2001-03-20 Japan Tobacco Inc. Propionic acid derivatives and applications thereof
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
EA200400011A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)

Also Published As

Publication number Publication date
WO2003074050A1 (en) 2003-09-12
US20030207924A1 (en) 2003-11-06
AR038881A1 (es) 2005-02-02
AP2004003124A0 (en) 2004-09-30
BR0308277A (pt) 2004-12-28
EA200400943A1 (ru) 2005-02-24
ES2310650T3 (es) 2009-01-16
NO20044242L (no) 2004-10-06
ECSP045285A (es) 2004-10-26
AU2003206059A1 (en) 2003-09-16
UY27695A1 (es) 2003-10-31
DE60323060D1 (de) 2008-10-02
CA2478520A1 (en) 2003-09-12
KR20040091693A (ko) 2004-10-28
ATE405260T1 (de) 2008-09-15
PA8567801A1 (es) 2003-11-12
TW200305403A (en) 2003-11-01
MXPA04007564A (es) 2004-11-10
JP2005528348A (ja) 2005-09-22
PE20030989A1 (es) 2003-11-29
IS7377A (is) 2004-07-29
ZA200406068B (en) 2005-09-06
OA12780A (en) 2006-07-07
TNSN04168A1 (fr) 2007-03-12
CO5601012A2 (es) 2006-01-31
PL372969A1 (en) 2005-08-08
EP1482935A1 (en) 2004-12-08
MA27181A1 (fr) 2005-01-03
EP1482935B1 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
HN2003000090A (es) Compuestos que modulan la actividad de ppar
HN2003000113A (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion
NI200300039A (es) Compuestos que modulan la actividad de ppar.
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
PA8568701A1 (es) Compuestos que modulan la actividad de ppar
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
SV2003001493A (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CR10900A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
BRPI0517088A (pt) formulação de comprimido estável
GT200100199A (es) Nuevos retinoides para el tratamiento de efisema.
CR8926A (es) Acidos de tiazolo-naftilo
AR021643A1 (es) Combinacion de cerivastatina y fibratos.
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo
CL2012001671A1 (es) Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.
HN2000000045A (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos.
UY26265A1 (es) Compuestos calciolíticos
BR112022012485A2 (pt) Agente profilático e/ou terapêutico para prostatite crônica/síndrome de dor pélvica crônica
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
CR9426A (es) Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares